BFC Planning’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$290K Buy
2,881
+550
+24% +$56.4K 0.01% 800
2026
Q2
$231K Hold
2,331
– – 0.01% 884
2026
Q1
$202K Buy
+2,331
New +$204K 0.01% 872
2025
Q2
– Sell
-300
Closed -$21.2K – 2757
2025
Q1
$21.2K Hold
300
– – ﹤0.01% 1433
2024
Q4
$19.7K Hold
300
– – ﹤0.01% 1458
2024
Q3
$21.2K Buy
+300
New +$20.9K ﹤0.01% 1426

Other funds holding IHE

BFC Planning's IHE Position: Q3 2026 in Review

BFC Planning increased its iShares US Pharmaceuticals ETF (IHE) stake by 24% in Q3 2026, buying an estimated $56.4K and bringing the position to 2,881 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #800.

BFC Planning first reported a position in IHE in Q3 2024 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold IHE as of Q3 2026.

  • BFC Planning held 2,881 shares of iShares US Pharmaceuticals ETF worth $290K as of Q3 2026.
  • BFC Planning bought 550 iShares US Pharmaceuticals ETF shares in Q3 2026, an estimated $56.4K.
  • iShares US Pharmaceuticals ETF made up 0.01% of BFC Planning's portfolio in Q3 2026, its #800 holding.
  • BFC Planning first reported a position in iShares US Pharmaceuticals ETF in Q3 2024 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.